Genmab A/S (NASDAQ:GMAB) Short Interest Update

Genmab A/S (NASDAQ:GMAB) saw a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 2,310,000 shares, a growth of 40.0% from the February 13th total of 1,650,000 shares. Based on an average trading volume of 1,370,000 shares, the days-to-cover ratio is currently 1.7 days. Currently, 0.4% of the company’s shares are sold short.

Institutional Investors Weigh In On Genmab A/S

Several large investors have recently bought and sold shares of GMAB. Deep Track Capital LP bought a new stake in Genmab A/S in the 4th quarter worth about $41,740,000. Brandywine Global Investment Management LLC bought a new stake in Genmab A/S in the 4th quarter worth about $33,804,000. Two Sigma Advisers LP boosted its position in Genmab A/S by 168.8% in the fourth quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company’s stock worth $34,509,000 after purchasing an additional 1,038,400 shares during the last quarter. Two Sigma Investments LP boosted its position in Genmab A/S by 122.2% in the fourth quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company’s stock worth $35,612,000 after purchasing an additional 938,455 shares during the last quarter. Finally, Marshall Wace LLP boosted its position in Genmab A/S by 162.2% in the fourth quarter. Marshall Wace LLP now owns 1,122,296 shares of the company’s stock worth $23,422,000 after purchasing an additional 694,243 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Stock Up 2.8 %

Shares of NASDAQ:GMAB traded up $0.55 on Friday, hitting $20.51. 953,591 shares of the company traded hands, compared to its average volume of 902,110. Genmab A/S has a 52 week low of $18.64 and a 52 week high of $31.02. The stock has a 50 day simple moving average of $21.24 and a 200-day simple moving average of $22.42. The company has a market cap of $13.57 billion, a PE ratio of 11.79, a PEG ratio of 2.65 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, sell-side analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on GMAB. Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. William Blair upgraded Genmab A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 11th. Leerink Partners upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a report on Thursday, February 13th. Finally, Truist Financial decreased their price objective on Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a report on Tuesday, March 11th. Four analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $41.33.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.